戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  binding mode similar to the natural product epoxomicin.
2 ST motif, or via proteasomal inhibition with epoxomicin.
3 pe generation is enhanced in the presence of epoxomicin.
4 teasome-specific inhibitors, lactacystin and epoxomicin.
5 he inhibitors MG115, MG132, lactacystin, and epoxomicin.
6 timalarial drug, or the proteasome inhibitor epoxomicin.
7                      Treatment of cells with epoxomicin (a proteasomal inhibitor) led to a dramatic i
8                                              Epoxomicin, a potent and selective inhibitor of the 20S
9  in Tg-CAPKN mice was partially inhibited by epoxomicin, a proteasome inhibitor.
10                     The proteasome inhibitor epoxomicin abolished the MyD88 degradation induced by TG
11                                              Epoxomicin also effectively inhibits NF-kappaB activatio
12 K inhibitor (U0126) or proteasome inhibitor (epoxomicin) also up-regulated Bim accumulation and rende
13 alues for the specific proteasome inhibitors epoxomicin and bortezomib for each of the catalytic site
14 em and the endosomal-lysosomal pathway using epoxomicin and chloroquine, respectively, further increa
15                    The proteasome inhibitors epoxomicin and MG132 significantly abrogated degradation
16 temically to mice, the proteasome inhibitors epoxomicin and proteasome inhibitor-1 increased bone vol
17 ces of the proteasome inhibitors bortezomib, epoxomicin, and Cbz-Leu(3)-aldehyde.
18 (1)-ATZ was inhibited by lactacystin, MG132, epoxomicin, and clasto-lactacystin beta-lactone.
19  cells to proteasome inhibitors (bortezomib, epoxomicin, and MG132), but not to proteotoxic or ER str
20                       Utilizing biotinylated-epoxomicin as a molecular probe, we demonstrate that epo
21                    These results thus define epoxomicin as a novel proteasome inhibitor that likely w
22   The proteasome inhibitors, lactacystin and epoxomicin, attenuated MIP-1beta induced CCR5 down-modul
23 wed that the proteasome inhibitors MG132 and epoxomicin blocked a postentry step in vaccinia virus (V
24 roteasome inhibitors MG132, lactacystin, and epoxomicin blocked PICT1 degradation, whereas the inhibi
25 lthough addition of the proteasome inhibitor epoxomicin blocked the presentation of two epitopes, pre
26        In contrast, the proteasome inhibitor epoxomicin caused a decrease in the levels of many of th
27      In that model, the proteasome inhibitor epoxomicin completely prevented LVH while blocking prote
28 fic inhibitors, lactacystin-beta-lactone and epoxomicin, could not stabilize HNE-modified proteins in
29 in as a molecular probe, we demonstrate that epoxomicin covalently binds to the LMP7, X, MECL1, and Z
30 d proteins in rat cortical neurons, although epoxomicin did.
31 t to peptide aldehyde proteasome inhibitors, epoxomicin does not inhibit nonproteasomal proteases suc
32 requirement for proteasomal processing of an epoxomicin-enhanced epitope, an in vitro proteasome dige
33 nfirm that both the epoxomicin-inhibited and epoxomicin-enhanced epitopes are processed cytosolically
34           Three closely related analogues of epoxomicin have been synthesized.
35                              The efficacy of epoxomicin in restoring function suggests that protease
36 ystin and the specific proteasomal inhibitor epoxomicin increased soluble protein levels of the poly(
37 G1 is stabilized by the inhibitors MG132 and epoxomicin, indicating that it is degraded by the 26S pr
38             To further confirm that both the epoxomicin-inhibited and epoxomicin-enhanced epitopes ar
39                                 In addition, epoxomicin is a more potent inhibitor of the chymotrypsi
40 synthesis of the potent proteasome inhibitor epoxomicin, is described.
41 esting that some other protein(s) induced by epoxomicin may regulate poly(Q) aggregation.
42 urs in the presence of proteasome inhibitors epoxomicin or bortezomib.
43 y injected six doses of naturally occurring (epoxomicin) or synthetic (Z-lle-Glu(OtBu)-Ala-Leu-al [PS
44 ed bovine erythrocyte proteasome reveal that epoxomicin potently inhibits primarily the chymotrypsin-
45                     The proteasome inhibitor epoxomicin raised ubiquitinated protein levels at least
46 bitors PSI (Z-Ileu-Glu(OtBu)-Ala-Leu-CHO) or epoxomicin recapitulated many of the degenerative change
47 e therefore evaluated a novel, irreversible, epoxomicin-related proteasome inhibitor, carfilzomib.
48 ith the proteasome inhibitors lactacystin or epoxomicin reversed m155 down-regulation of H60.
49                                         With epoxomicin, soluble p62/SQSTM1 associated with proteasom
50 ow that the potent antitumor natural product epoxomicin specifically targets the proteasome.
51 ect was reversed by the proteasome inhibitor epoxomicin, suggesting a Sir2alpha-mediated ubiquitin/pr
52  PC12 cell model, aggregation was reduced by epoxomicin, suggesting that some other protein(s) induce
53 binding of the proteasome-specific inhibitor epoxomicin to BPH.
54        Furthermore, administration of PSI or epoxomicin to monkeys in an attempt to extend the model
55                                              Epoxomicin treatment also rescued intercellular transfer
56 nce it is prevented by either lactacystin or epoxomicin, two inhibitors of proteasomal degradation.
57 , and by the proteasome inhibitors MG132 and epoxomicin, which prolong GHR signaling to STAT5b.
58  replication was inhibited by both MG132 and epoxomicin, which would account for the effect on interm